GlassScriptPhysician profile
Samer Al-Kaade
NPI 1982648259
$89,415.69
in general payments reported to CMS, 2019-2025
40 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $18K · 2021: $8,319 · 2022: $6,578 · 2023: $6,486 · 2024: $11K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $7,028 · Honoraria: $5,145 · Travel and Lodging: $883 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,150.00 |
| Food and Beverage | $7,028.46 |
| Honoraria | $5,145.00 |
| Travel and Lodging | $883.25 |
| Education | $117.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $78,313.24 | 2019-2025 | Creon, Rinvoq, Skyrizi |
| Aimmune Therapeutics, INC. | $5,366.08 | 2023-2025 | Zenpep, Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $910.39 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $506.73 | 2023-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $467.74 | 2022-2025 | Dupixent |
| Genzyme Corporation | $408.70 | 2022-2025 | |
| Madrigal Pharmaceuticals | $314.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $299.33 | 2023-2025 | Tremfya, Stelara |
| Celgene Corporation | $286.73 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $269.52 | 2022-2025 | Sucraid, Sucraid |
| Pfizer INC. | $268.50 | 2022-2025 | |
| Ardelyx, INC. | $222.55 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $193.58 | 2019-2025 | Apollo Esg Nxt System |
| Intercept Pharmaceuticals, INC. | $175.56 | 2022-2025 | Ocaliva |
| Globus Medical, INC. | $132.06 | 2025 | Senza |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Al-Kaade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.